Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy

Octavi Córdoba1, Elisa Llurba2, Javier Cortés3, M Dolors Sabadell1, José Luis Lirola4, Queralt Ferrer5, and Jordi Xercavins1

1Breast Unit and 2Fetal and Maternal Medicine Unit, Service of Obstetrics and Gynecology; 3Service of Oncology, 4Service of Pathology, and 5Service of Pediatrics, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain

ABSTRACT

We describe the case of a pregnant woman diagnosed with breast cancer at 26 weeks’ gestation. The tumor was positive for estrogen and progesterone receptors and negative for overexpression of c-erbB-2 protein. Neoadjuvant FAC (fluorouracil, adriamycin, cytoxan) chemotherapy was started at 29 weeks’ gestation. At 37 weeks, delivery was induced and the patient gave birth to a healthy female baby weighing 2350 g, after which she was given a further cycle of chemotherapy and weekly paclitaxel. Clinical and radiological remission was achieved. Resection of the breast tissue showed complete pathological response and negative lymph nodes. This case illustrates how the integrated work of different specialists can obtain excellent oncological and obstetrical results in the care of pregnant women with breast cancer. Free full text available at www.tumorionline.it

Key words: breast cancer, estrogen receptors, FAC chemotherapy, paclitaxel, pregnancy.

Acknowledgments: We thank Marta Pulido, MD, for editing the manuscript and editorial assistance.

Research support: None.

Authors’ disclosure of potential conflicts of interest: The authors indicated no potential conflicts of interest.

Correspondence to: Octavi Córdoba, MD, Breast Unit, Service of Obstetrics and Gynecology, Hospital Materno-infantil Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain. Tel +34-93-4893066; fax +34-93-4893039, e-mail ocordoba@vhebron.net

Received August 27, 2009; accepted December 1, 2009.